Abiraterone acetate treatment in patients with castration-resistant prostate cancer with visceral metastases: a real-world experience
2019
In the pre-chemotherapy (CT) and post-CT settings of metastatic castration-resistant prostate cancer (mCRPC), abiraterone acetate plus prednisone (AAP) significantly extended median overall survival and radiographic progression-free survival (PFS) compared with prednisone alone. Yet, few data are av
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
22
References
7
Citations
NaN
KQI